Pro-Dex (PDEX) to Release Quarterly Earnings on Monday

Pro-Dex (NASDAQ:PDEX) is expected to issue its Q4 2026 results after the market closes on Monday, August 31st. Analysts expect Pro-Dex to announce earnings of $0.67 per share and revenue of $19.20 million for the quarter. Individuals may visit the the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Friday, September 4, 2026 at 4:00 PM ET.

Pro-Dex Trading Down 3.5%

Shares of NASDAQ:PDEX opened at $62.56 on Friday. Pro-Dex has a 52-week low of $23.47 and a 52-week high of $69.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.14 and a current ratio of 3.67. The company has a market capitalization of $199.57 million, a P/E ratio of 17.28 and a beta of 0.02. The company has a 50-day simple moving average of $61.96 and a 200 day simple moving average of $55.94.

Institutional Investors Weigh In On Pro-Dex

Several hedge funds have recently bought and sold shares of PDEX. Wells Fargo & Company MN grew its holdings in Pro-Dex by 65.4% in the 4th quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock valued at $89,000 after buying an additional 915 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Pro-Dex during the fourth quarter worth $37,000. Bank of America Corp DE boosted its position in shares of Pro-Dex by 173.3% in the second quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 1,073 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Pro-Dex in the second quarter valued at about $50,000. Finally, Osaic Holdings Inc. grew its stake in shares of Pro-Dex by 23.6% in the second quarter. Osaic Holdings Inc. now owns 7,120 shares of the medical instruments supplier’s stock valued at $311,000 after acquiring an additional 1,360 shares in the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PDEX has been the topic of several research analyst reports. Zacks Research upgraded Pro-Dex to a “hold” rating in a research note on Tuesday, May 19th. Ascendiant Capital Markets lifted their target price on Pro-Dex from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded Pro-Dex from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings downgraded Pro-Dex from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $70.00.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.